Author(s): Parent O; Alasmar Z; Osborne S; Bussy A; Costantino M; Fouquet JP; Quesada D; Pastor-Bernier A; Fajardo-Valdez A; Pichet-Binette A; McQuarrie A; Maranzano J; Devenyi GA; Steele CJ; Villeneuve S; ; Dadar M; Chakravarty MM;

White matter hyperintensities (WMHs) are neuroimaging markers widely interpreted as caused by cerebral small vessel disease, yet emerging evidence suggests that a subset may have a neurodegenerative etiology. Current imaging methods have lacked the specificity to disentangle biological processes ...

Article GUID: 40585093

Author(s): Smith EE; Phillips NA; Feldman HH; Borrie M; Ganesh A; Henri-Bhargava A; Desmarais P; Frank A; Badhwar A; Barlow L; Bartha R; Best S; Bethell J; Bhangu J; Black SE; Bocti C; Bronskill SE; Burhan AM; Calon F; Camicioli R; Campbell B; Coll ...

Lecanemab and donanemab are monoclonal antibody therapies that remove amyloid-beta from the brain. They are the first therapies that alter a fundamental mechanism, amyloid-beta deposition, in Alzheimer disease (AD). To inform Canadian decisions on approval and use of these drugs, the Canadian Con ...

Article GUID: 39893139

Author(s): Boucetta S, Salimi A, Dadar M, Jones BE, Collins DL, Dang-Vu TT

Sci Rep. 2016 06 01;6:26782 Authors: Boucetta S, Salimi A, Dadar M, Jones BE, Collins DL, Dang-Vu TT

Article GUID: 27245317